TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:43
Alto Neuroscience Inc. ( ANRO ) https://www.altoneuroscience.com
4.42USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ANRO
0.00%
SPY
32.66%
ANRO
0.00%
SPY
108.59%
ANRO
0.00%
SPY
302.52%
ANRO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
119.16
-46.34
0.27
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.07
320.32
0.72
-14.79
0.00
0.66
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-3867.20
-26.08
-4697.72
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
210.81
-111.63
0.00
Other Earnings and Cash Flow Stats:
Alto Neuroscience Inc. ( ANRO ) Net Income TTM ($MM) is -57.45
Alto Neuroscience Inc. ( ANRO ) Operating Income TTM ($MM) is -63.38
Alto Neuroscience Inc. ( ANRO ) Owners' Earnings Annual ($MM) is 0.00
Alto Neuroscience Inc. ( ANRO ) Current Price to Owners' Earnings ratio is 0.00
Alto Neuroscience Inc. ( ANRO ) EBITDA TTM ($MM) is -62.89
Alto Neuroscience Inc. ( ANRO ) EBITDA Margin is -4697.72%
Capital Allocation:
Alto Neuroscience Inc. ( ANRO ) has paid 0.00 dividends per share and bought back -0.075012000000001 million shares in the past 12 months
Alto Neuroscience Inc. ( ANRO ) has increased its debt by 6.093 million USD in the last 12 months
Capital Structure:
Alto Neuroscience Inc. ( ANRO ) Interest-bearing Debt ($MM) as of last quarter is 16
Alto Neuroscience Inc. ( ANRO ) Annual Working Capital Investments ($MM) are -7
Alto Neuroscience Inc. ( ANRO ) Book Value ($MM) as of last quarter is 165
Alto Neuroscience Inc. ( ANRO ) Debt/Capital as of last quarter is 9%
Other Balance Sheet Stats:
Alto Neuroscience Inc. ( ANRO ) has 181 million in cash on hand as of last quarter
Alto Neuroscience Inc. ( ANRO ) has 14 million of liabilities due within 12 months, and long term debt 10 as of last quarter
Alto Neuroscience Inc. ( ANRO ) has 26 common shares outstanding as of last quarter
Alto Neuroscience Inc. ( ANRO ) has 0 million USD of preferred stock value
Academic Scores:
Alto Neuroscience Inc. ( ANRO ) Altman Z-Score is 1.65 as of last quarter
Alto Neuroscience Inc. ( ANRO ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Alto Neuroscience Inc. ( ANRO ) largest shareholder is owning shares at 0.00 ($MM) value
Savitz Adam(an insider) Bought 2931 shares of Alto Neuroscience Inc. ( ANRO ) for the amount of $38747.82 on 2024-07-10
7.51% of Alto Neuroscience Inc. ( ANRO ) is held by insiders, and 91.30% is held by institutions
Alto Neuroscience Inc. ( ANRO ) went public on 2024-02-02
Other Alto Neuroscience Inc. ( ANRO ) financial metrics:
FCF:-47.85
Unlevered Free Cash Flow:0.00
EPS:-2.49
Operating Margin:-3867.20
Gross Profit Margin:-26.08
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-40.67
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Alto Neuroscience Inc. ( ANRO ) :
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.